Financials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 02-07-2026 at the NBB all 4 filings
2022 to 2025, 4 financial years
The operating result for 2025 is nearly 4.1 times that of 2024. It is a recovery after the fall in 2024.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Human health activities (NACE 86). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Investments
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Tangible fixed assets | €41,570 | - | - | - |
| Depreciation and write-downs of the year | €32 | €8,314 | €8,314 | €8,314 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Comparable companies
These companies have the same main activity as HASHIMOTO: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €521,000 and €2.1m, founded between 2017 and 2023.
| Company | Founded | Total assets | Equity | Gross margin | Net result | Financial year |
|---|---|---|---|---|---|---|
| HASHIMOTO Roeselare | 2021 | €1.4m | €0.01m | €0.01m | - | 2025 |
| Associatie GZA SA SV Anesthesie, Intensieve Zorgen, en Pijnkliniek Antwerpen | 2019 | €1.4m | €0.06m | €0.01m | €0.006m | 2025 |
| Docteur Crémers Liège | 2020 | €0.7m | €0.2m | €0.01m | -€0.02m | 2025 |
| MVGclinic Schilde | 2023 | €2.1m | -€0.3m | €0.02m | -€0.08m | 2025 |
| Inwendige Ziekten Sint-Trudo Sint-Truiden | 2018 | €1.3m | €0.02m | €0.02m | -€0.001m | 2025 |
| Associatie Urologie Hageland Tielt-Winge | 2017 | €1.1m | €0.009m | €0.02m | €167 | 2025 |
| LOHEZO Heusden-Zolder | 2023 | €0.5m | €0.007m | €0.01m | -€235 | 2025 |
They were chosen from the 8,159 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | €1,340 | €1,484 | €2,592 | €1,757 | ▼ 32.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €32 | €8,314 | €8,314 | €8,314 | = |
| Other operating charges640/8 | €262 | €215 | €1,194 | €1,226 | ▲ 2.8% |
| Gross operating margin9900 | €1,452 | €18,871 | €12,239 | €11,867 | ▼ 3.0% |
| Operating profit (loss)9901 | -€183 | €8,858 | €140 | €570 | ▲ 307% |
| Financial income75/76B | €418 | €1 | €0 | - | - |
| Recurring financial income75 | €418 | €1 | €0 | - | - |
| Financial charges65/66B | €235 | €209 | €140 | €244 | ▲ 74.2% |
| Recurring financial charges65 | €235 | €209 | €140 | €244 | ▲ 74.2% |
| Profit (loss) for the period before taxes9903 | - | €8,649 | €0 | €326 | - |
| Income taxes67/77 | - | - | - | €326 | - |
| Profit (loss) for the period9904 | - | €8,649 | €0 | - | - |
| Profit (loss) for the period to be appropriated9905 | - | €8,649 | €0 | - | - |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €1.0m | €1.1m | €1.1m | €1.4m | ▲ 21.9% |
| Fixed assets21/28 | €0.04m | €0.03m | €0.02m | €0.02m | ▼ 33.4% |
| Tangible fixed assets22/27 | €0.04m | €0.03m | €0.02m | €0.02m | ▼ 33.4% |
| Plant, machinery and equipment23 | €0.04m | €0.03m | €0.02m | €0.02m | ▼ 33.4% |
| Current assets29/58 | €1.0m | €1.0m | €1.1m | €1.4m | ▲ 23.2% |
| Amounts receivable within one year40/41 | €0.7m | €0.9m | €0.9m | €1.0m | ▲ 11.6% |
| Other amounts receivable41 | €0.7m | €0.9m | €0.9m | €1.0m | ▲ 11.6% |
| Cash at bank and in hand54/58 | €0.3m | €0.2m | €0.2m | €0.4m | ▲ 74.6% |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €1.0m | €1.1m | €1.1m | €1.4m | ▲ 21.9% |
| Equity10/15 | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Contributions10/11 | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Profit (loss) carried forward14 | - | €0 | €0 | - | - |
| Amounts payable17/49 | €1.0m | €1.1m | €1.1m | €1.4m | ▲ 22.1% |
| Amounts payable within one year42/48 | €1.0m | €1.1m | €1.1m | €1.4m | ▲ 21.4% |
| Trade debts44 | €0.1m | €0.1m | €0.1m | €0.1m | ▼ 3.1% |
| Suppliers440/4 | €0.1m | €0.1m | €0.1m | €0.1m | ▼ 3.1% |
| Other amounts payable47/48 | €0.9m | €0.9m | €1.0m | €1.2m | ▲ 24.4% |
| Accrued charges and deferred income492/3 | - | - | - | €0.008m | - |
| Line | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | - | €8,649 | €0 | - | - |
| + Depreciation and write-downs630 | €32 | €8,314 | €8,314 | €8,314 | = |
| Operating cash flow (approximation) | €32 | €16,963 | €8,314 | €8,314 | = |
| Investment in fixed assets (approximation) | - | €0 | €0 | €0 | - |
| Change in cash | - | -€99,157 | €30,727 | €151,407 | ▲ 393% |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.